C. Warren Olanow

70.4k total citations · 17 hit papers
303 papers, 40.6k citations indexed

About

C. Warren Olanow is a scholar working on Neurology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, C. Warren Olanow has authored 303 papers receiving a total of 40.6k indexed citations (citations by other indexed papers that have themselves been cited), including 254 papers in Neurology, 114 papers in Cellular and Molecular Neuroscience and 38 papers in Molecular Biology. Recurrent topics in C. Warren Olanow's work include Parkinson's Disease Mechanisms and Treatments (216 papers), Neurological disorders and treatments (158 papers) and Nuclear Receptors and Signaling (38 papers). C. Warren Olanow is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (216 papers), Neurological disorders and treatments (158 papers) and Nuclear Receptors and Signaling (38 papers). C. Warren Olanow collaborates with scholars based in United States, Italy and Canada. C. Warren Olanow's co-authors include Jeffrey H. Kordower, José Á. Obeso, Daniel P. Perl, Thomas B. Freeman, Kevin St. P. McNaught, Robert A. Hauser, W. G. Tatton, Fabrizio Stocchi, Christopher G. Goetz and Yaping Chu and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

C. Warren Olanow

299 papers receiving 39.7k citations

Hit Papers

MDS clinical diagnostic c... 1990 2026 2002 2014 2015 2008 1999 2003 1990 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MDS clinical diagnostic criteria for Parkinson's disease
    2015 4.8k citations Ronald B. Postuma, Daniela Berg et al. Movement Disorders profile →
  2. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
    2008 1.2k citations Jeffrey H. Kordower, Yaping Chu et al. profile →
  3. ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
    1999 1.2k citations C. Warren Olanow, W. G. Tatton profile →
  4. A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
    2003 1.1k citations C. Warren Olanow, Christopher G. Goetz et al. Annals of Neurology profile →
  5. Variable expression of Parkinson's disease
    1990 1.0k citations Christopher G. Goetz, William C. Koller et al. Neurology profile →
  6. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
    2013 892 citations Jeffrey H. Kordower, C. Warren Olanow et al. profile →
  7. MDS research criteria for prodromal Parkinson's disease
    2015 876 citations Daniela Berg, Ronald B. Postuma et al. Movement Disorders profile →
  8. Oxidative stress and the pathogenesis of Parkinson's disease
    1996 815 citations C. Warren Olanow et al. Neurology profile →
  9. Neuropathological Evidence of Graft Survival and Striatal Reinnervation after the Transplantation of Fetal Mesencephalic Tissue in a Patient with Parkinson's Disease
    1995 671 citations Jeffrey H. Kordower, Thomas B. Freeman et al. New England Journal of Medicine profile →
  10. The scientific and clinical basis for the treatment of Parkinson disease (2009)
    2009 644 citations C. Warren Olanow et al. Neurology profile →
  11. A radical hypothesis for neurodegeneration
    1993 643 citations C. Warren Olanow profile →
  12. Pathophysiology of the basal ganglia in Parkinson's disease
    2000 638 citations José Á. Obeso, C. Warren Olanow et al. profile →
  13. A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
    2009 587 citations C. Warren Olanow, Olivier Rascol et al. New England Journal of Medicine profile →
  14. Understanding cell death in parkinson's disease
    1998 582 citations Peter Jenner, C. Warren Olanow Annals of Neurology profile →
  15. Evidence of neuronal oxidative damage in Alzheimer's disease.
    1996 515 citations C. Warren Olanow, Daniel P. Perl et al. profile →
  16. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
    2013 487 citations C. Warren Olanow, Karl Kieburtz et al. The Lancet Neurology profile →
  17. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
    2015 388 citations Benjamin Dehay, Mathieu Bourdenx et al. The Lancet Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Warren Olanow United States 94 26.9k 15.7k 9.2k 5.5k 4.7k 303 40.6k
Étienne C. Hirsch France 89 16.2k 0.6× 15.1k 1.0× 9.2k 1.0× 4.6k 0.8× 7.2k 1.5× 311 31.8k
Yves Agid France 120 31.6k 1.2× 25.5k 1.6× 12.9k 1.4× 6.4k 1.2× 8.3k 1.8× 608 55.1k
Stanley Fahn United States 98 23.9k 0.9× 13.5k 0.9× 5.2k 0.6× 4.1k 0.8× 3.3k 0.7× 495 34.4k
Serge Przedborski United States 110 21.8k 0.8× 15.3k 1.0× 14.3k 1.6× 7.8k 1.4× 8.4k 1.8× 261 41.6k
Patrik Brundin Sweden 97 15.5k 0.6× 17.7k 1.1× 14.5k 1.6× 5.6k 1.0× 5.2k 1.1× 363 35.5k
Peter Jenner United Kingdom 81 15.2k 0.6× 12.5k 0.8× 9.3k 1.0× 4.2k 0.8× 3.3k 0.7× 463 31.0k
Peter Riederer Germany 91 11.0k 0.4× 12.2k 0.8× 9.8k 1.1× 7.6k 1.4× 6.0k 1.3× 534 35.4k
Anthony H.V. Schapira United Kingdom 104 21.8k 0.8× 12.8k 0.8× 17.5k 1.9× 9.1k 1.7× 4.5k 1.0× 480 43.1k
Paolo Calabresi Italy 98 11.5k 0.4× 18.3k 1.2× 9.9k 1.1× 5.0k 0.9× 4.1k 0.9× 632 34.1k
Joseph Jankovic United States 122 45.1k 1.7× 19.4k 1.2× 6.4k 0.7× 6.7k 1.2× 5.9k 1.3× 815 59.9k

Countries citing papers authored by C. Warren Olanow

Since Specialization
Citations

This map shows the geographic impact of C. Warren Olanow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Warren Olanow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Warren Olanow more than expected).

Fields of papers citing papers by C. Warren Olanow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Warren Olanow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Warren Olanow. The network helps show where C. Warren Olanow may publish in the future.

Co-authorship network of co-authors of C. Warren Olanow

This figure shows the co-authorship network connecting the top 25 collaborators of C. Warren Olanow. A scholar is included among the top collaborators of C. Warren Olanow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Warren Olanow. C. Warren Olanow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Olanow, C. Warren, Deborah McIntyre, Michele Matarazzo, et al.. (2024). Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study. Movement Disorders. 39(6). 945–954. 5 indexed citations
2.
Kieburtz, Karl, Russell Katz, Andrew McGarry, & C. Warren Olanow. (2020). A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic. Movement Disorders. 36(1). 59–63. 15 indexed citations
3.
4.
Olanow, C. Warren & Fabrizio Stocchi. (2016). Safinamide – A New Therapeutic Option to Address Motor Symptoms and Motor Complications in Mid- to Late-stage Parkinson’s Disease. European Neurological Review. 11. 2–15. 7 indexed citations
5.
Bartus, Raymond T., Jeffrey H. Kordower, Eugene M. Johnson, et al.. (2015). Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies. Neurobiology of Disease. 78. 162–171. 63 indexed citations
6.
Dehay, Benjamin, Mathieu Bourdenx, Philippe Gorry, et al.. (2015). Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. The Lancet Neurology. 14(8). 855–866. 388 indexed citations breakdown →
7.
Berg, Daniela, Ronald B. Postuma, Bastiaan R. Bloem, et al.. (2014). Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders. 29(4). 454–462. 341 indexed citations
8.
Rascol, Olivier, Paolo Barone, Madhuri Behari, et al.. (2012). Perampanel in Parkinson Disease Fluctuations. Clinical Neuropharmacology. 35(1). 15–20. 45 indexed citations
9.
Schapira, Anthony H.V. & C. Warren Olanow. (2009). Drug selection and timing of initiation of treatment in early Parkinson's disease. Annals of Neurology. 64(S2). S47–S55. 49 indexed citations
10.
Olanow, C. Warren, Jean‐Michel Graciès, Christopher G. Goetz, et al.. (2008). Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video‐based analysis. Movement Disorders. 24(3). 336–343. 68 indexed citations
11.
McNaught, Kevin St. P., Alexander Kapustin, P. Shashidharan, et al.. (2004). Brainstem pathology in DYT1 primary torsion dystonia. Annals of Neurology. 56(4). 540–547. 104 indexed citations
12.
Bhattacharya, Kirsty, Soraya Nouri, C. Warren Olanow, Melvin D. Yahr, & Horacio Kaufmann. (2003). Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. Parkinsonism & Related Disorders. 9(4). 221–224. 22 indexed citations
13.
14.
McNaught, Kevin St. P., et al.. (2002). Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport. 13(11). 1437–1441. 211 indexed citations
15.
Olanow, C. Warren & Fabrizio Stocchi. (2000). Why delaying levodopa is a good treatment strategy in early Parkinson's disease. European Journal of Neurology. 7(s1). 3–8. 5 indexed citations
16.
Olanow, C. Warren & J. A. Obeso. (2000). The role of comt inhibitors in the treatment of Parkinson's disease. 1 indexed citations
17.
Freeman, Thomas B., Dorothy E. Vawter, P E Leaverton, et al.. (1999). Use of Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson's Disease. New England Journal of Medicine. 341(13). 988–992. 157 indexed citations
18.
Tatton, W. G. & C. Warren Olanow. (1999). Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1410(2). 195–213. 211 indexed citations
19.
Olanow, C. Warren, et al.. (1996). Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47(6_suppl_3). S161–70. 815 indexed citations breakdown →
20.
Olanow, C. Warren, et al.. (1996). Patients taking selegiline may have received more levodopa than necessary: Table 1. BMJ. 312(7032). 702.3–703. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Étienne C. Hirsch Breakdown of academic impact, for papers by Yves Agid Breakdown of academic impact, for papers by Stanley Fahn Breakdown of academic impact, for papers by Serge Przedborski Breakdown of academic impact, for papers by Patrik Brundin Breakdown of academic impact, for papers by Peter Jenner Breakdown of academic impact, for papers by Peter Riederer Breakdown of academic impact, for papers by Anthony H.V. Schapira Breakdown of academic impact, for papers by Paolo Calabresi Breakdown of academic impact, for papers by Joseph Jankovic
Rankless by CCL
2026